Efficacy of Human Umbilical Cord Blood-Mononuclear Cell Transplantation for MSA Treatment and Its Effects on Changes in T-Cell Subsets in Peripheral Blood and Inflammatory Factors

Abstract

Objective. This study is aimed at examining the efficacy of human umbilical cord blood-mononuclear cell (hUCB-MNCs) transplantation through lateral atlanto-occipital space puncture in multiple system atrophy (MSA) treatment and investigating changes in T-cell subsets in peripheral blood and inflammatory factors in patients before and after treatment. Methods. A total of 20 patients with MSA who underwent hUCB-MNC transplantation through lateral atlanto-occipital space puncture in the Liaocheng People’s Hospital were enrolled. Patients were followed up at 0, 1, 3, and 6 months after treatment, and the Unified Multiple System Atrophy Rating Scale (UMSARS) scores, TNF-α in the peripheral blood, IL-6, percentage of CD4, and CD4/CD8 ratio were evaluated and compared for each follow-up point; any adverse effects were recorded. Results. UMSARS Part I scores were 20.55 ± 3.80 , 19.20 ± 3.78 , and 19.40 ± 4.11 , 1, 3, and 6 months, respectively, after treatment and were significantly lower as compared to that before treatment ( 23.50 ± 4.72 ; P < 0.05 ). Similarly, UMSARS Part II scores 1, 3, and 6 months after treatment were 25.50 ± 5.01 , 24.05 ± 5.01 , and 24.25 ± 5.05 , respectively, significantly lower as compared to that before treatment ( 30.15 ± 5.63 ; P < 0.05 ). The IL-6 values in the peripheral blood 1, 3, and 6 months after treatment were 5.25 ± 2.70 pg / m , 2.96 ± 1.75 pg / m , and 3.31 ± 1.62 pg / m , respectively, which were significantly lower ( P < 0.05 ) than that before treatment ( 8.22 ± 4.69 ) pg/m. The TNF-α levels at 3 and 6 months after treatment were 13.08 ± 6.13 pg / m and 12.24 ± 4.76 pg / m , respectively, which were significantly lower than that before treatment ( 22.99 ± 13.30 ; P < 0.01 ). The CD4/CD8 ratios in the peripheral blood 1, 3, and 6 months after treatment were 1.09 ± 0.25 , 1.30 ± 0.24 , and 1.43 ± 0.22 , respectively, which were significantly different than that before treatment ( 0.81 ± 0.24 , P < 0.01 ). Similarly, the CD4 percentages 1, 3, and 6 months after treatment were 34.09 ± 1.79 , 36.05 ± 1.50 , and 36.47 ± 1.47 , respectively, which were significantly different than that before treatment ( 0.81 ± 0.24 ; P < 0.01 ). Conclusion. hUCB-MNC transplantation through lateral atlanto-occipital space puncture could significantly improve the symptoms and signs in patients with MSA and delay the disease progression. Thus, hUCB-MNCs may modulate immune activity and reduce the inflammatory response.

Human Umbilical Cord Blood Mononuclear Cells Ameliorate CCl4-Induced Acute Liver Injury in Mice via Inhibiting Inflammatory Responses and Upregulating Peripheral Interleukin-22

“…IL-6 activates downstream signal through p-STAT3 in the liver, which confers resistance to liver damage (Schmidt-Arras and Rose-John, 2016). However, it was reported that mRNA and protein levels of IL-6 were both inhibited after treatment of hUCBMNCs (Rosenkranz et al, 2012;Yu et al, 2021), which are parallel to our study. The inhibition of IL-6 expression by hUCBMNCs in the early stage of liver injury would theoretically lead to the inhibition of liver regeneration which might be harmful for liver repair.…”

Effects of human umbilical cord blood mononuclear cells on ovalbumin-induced asthma in mice

“…Compared with MNCs obtained from adult bone marrow MNCs (BMMNCs), umbilical cord blood MNCs (UCMNCs) have higher cell viability and lower reaction to cytotoxic T cells and T-helper (Th)1 cells ( 5 ). The therapeutic potential of UCMNCs has been reported in many animal models involving bronchopulmonary dysplasia ( 6 ), neonatal lung injury ( 7 ), and acute myocardial infarction ( 8 ), and in some clinical studies for diseases such as multiple system atrophy ( 9 ) and spastic cerebral palsy ( 10 ). The non-invasiveness, high accessibility, and few ethical constraints of UCMNCs make them a suitable alternative to BMMNCs.…”